-
New Ypsilon and Ypsilon hf
-
The Cupra Raval will be launched in 2026
-
New id.Polo comes electric
-
Iran defies US threats to insist on right to enrich uranium
-
Seifert powers New Zealand to their record T20 World Cup chase
-
Naib's fifty lifts Afghanistan to 182-6 against New Zealand
-
Paul Thomas Anderson wins top director prize for 'One Battle After Another'
-
De Beers sale drags in diamond doldrums
-
NFL embraces fashion as league seeks new audiences
-
What's at stake for Indian agriculture in Trump's trade deal?
-
Real Madrid can wait - Siraj's dream night after late T20 call-up
-
Castle's monster night fuels Spurs, Rockets rally to beat Thunder
-
Japan votes in snow-hit snap polls as Takaichi eyes strong mandate
-
Pakistan's capital picks concrete over trees, angering residents
-
Berlin's crumbling 'Russian houses' trapped in bureaucratic limbo
-
Neglected killer: kala-azar disease surges in Kenya
-
Super Bowl set for Patriots-Seahawks showdown as politics swirl
-
Sengun shines as Rockets rally to beat NBA champion Thunder
-
Matsuyama grabs PGA Phoenix Open lead with Hisatsune one back
-
Washington Post CEO out after sweeping job cuts
-
Haiti's transitional council hands power to PM
-
N. Korea to hold party congress in February, first since 2021
-
Thailand votes after three leaders in two years
-
Swiss joy as Von Allmen wins first gold of Winter Olympics
-
George backs England to 'kick on' after Six Nations rout of Wales
-
Malinin upstaged as Japan keep pressure on USA in skating team event
-
Vail's golden comets Vonn and Shiffrin inspire those who follow
-
Veteran French politician loses culture post over Epstein links
-
Japan's Kimura wins Olympic snowboard big air gold
-
Arteta backs confident Gyokeres to hit 'highest level'
-
Hojlund the hero as Napoli snatch late win at Genoa
-
England's Arundell 'frustrated' despite hat-trick in Wales romp
-
Lollobrigida skates to first Italian gold of Winter Olympics on her birthday
-
Arundell hat-trick inspires England thrashing of Wales in Six Nations opener
-
Chile's climate summit chief to lead plastic pollution treaty talks
-
Rosenior hails 'unstoppable' Palmer after treble tames Wolves
-
French ex-minister offers resignation from Paris cultural hub over Epstein links
-
New NBA dunk contest champ assured and shooting stars return
-
Shiffrin says will use lessons learnt from Beijing flop at 2026 Games
-
Takaichi tipped for big win as Japan votes
-
Lens return top of Ligue 1 with win over Rennes
-
Shiffrin learning from Beijing lessons ahead of Milan-Cortina bow
-
Demonstrators in Berlin call for fall of Iran's Islamic republic
-
'Free the mountains!": clashes at Milan protest over Winter Olympics
-
Townsend accepts pressure will mount on him after Italy defeat
-
BMW iX3 new style and design
-
Suryakumar's 84 leads India to opening win over USA in T20 World Cup
-
Lollobrigida skates to first Italian gold of Milan-Cortina Games
-
Barca beat Mallorca to extend Liga lead
-
Gyokeres lifts Arsenal nine clear as Man Utd pile pressure on Frank
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
L.Durand--AMWN